ArticleBone marrow transplantation2025

Outcomes of patients with Hodgkin lymphoma receiving Brentuximab Vedotin (BV) as maintenance therapy after ASCT according to previous exposure to BV. A retrospective analysis of the EBMT Lymphoma Working Party in collaboration with GELTAMO, FIL, LYSA, and Turkish Lymphoma Group.

Carmen Martínez et al.PubMed ↗Publisher ↗

No numbers read from the abstract.